A 16 week randomized, double-blind, parallel group study to evaluate the efficacy and safety of a new medication (GSK523338) to lower LDL-c [low density lipoprotein cholesterol] and HbA1c [proportion of glycosylated haemoglobin] in subjects with type 2 diabetes mellitus.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs GSK 523338 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- 02 Jul 2018 Biomarkers information updated
- 14 Jun 2007 Status changed from recruiting to completed.
- 25 Oct 2006 New trial record.